In terms of clinical evolution after treatment, the biological evolution in the series of Verhelst et al. [10] noticed a normalization of PRL in 84% of patients, 92% of microprolactinomas, and 77% of macroprolactinomas, whereas in the series of Colao et al. [12] the normalization of prolactin level concerned 61% of microprolactinomas and 47% of macroprolactinomas. The gene discussed is PRL; the disease is Microprolactinoma.